Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25783651 | 0.81 | PKM (0.50) | PKMKDM4EKMT2ATHRB | |
| SCHEMBL20910305 | 0.79 | PKM (0.48) | PKMKDM4EKMT2AHSD11B1HSD11B2 | |
| SCHEMBL12736739 | 0.79 | SPHK1 (0.38) | THRB | |
| SCHEMBL4449130 | 0.78 | THRB (0.37) | PKMKDM4EKMT2ATHRB | |
| SCHEMBL13157085 | 0.76 | THRB (0.33) | KDM4EKMT2ATHRB | |
| SCHEMBL1679811 | 0.74 | HSD11B1 (0.39) | THRBHSD11B1 | |
| SCHEMBL2199488 | 0.73 | KDM4E (0.39) | PKMKDM4EKMT2A | |
| SCHEMBL17132562 | 0.73 | THRB (0.34) | THRB | |
| SCHEMBL4317039 | 0.73 | THRB (0.34) | PKMTHRB | |
| SCHEMBL17226613 | 0.72 | PKM (0.56) | PKMKDM4EKMT2AHSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932280-B2 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME CORP. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932280-B2 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME CORP. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090036503-A1 | Triazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | MERCK SHARP & DOHME LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090036503-A1 | Triazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | MERCK SHARP & DOHME LLC | 2009-02-05 | — | — | US | disclosed |
| WO-2007087150-A2 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036503-A1 | Triazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | HSD11B1, HSD17B1, HSD3B1 | PKM 1889/4885KDM4E 4025/4885KMT2A 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.